BioProcess International Asia 2025
Kyoto, Japan
October 20–22, 2025
Genedata Japan will be taking part in BioProcess International Asia 2025 held in Kyoto, Japan.
Don't miss the opportunity to see how Genedata solutions efficiently support the whole biopharmaceutical R&D workflow, including screening and protein engineering, expression and purification, characterization and analysis of protein therapeutics, cell line design and development, bioprocess optimization, stratification of clinical trial subjects, and quality control of biologicals.
For more information about Genedata solutions, please contact info(at)genedata.com (English) or japan(at)genedata.com (Japanese).
Recommended Oral Presentation
Genedata E2E Platform for Digital Transformation in Bioprocessing
Mizue Hisano, Ph.D., Scientific Business Consultant, Genedata AG
Wednesday, October 22 | 9:30 - 10:00 am
The Genedata E2E Platform, also known as Genedata Bioprocess®, is designed to unify fragmented digital ecosystems in bioprocess development by integrating data from ELNs, LIMS, and data lakes to streamline decision-making and process analytical technology (PAT) implementation. The platform manages all stages of bioprocessing, including upstream and downstream processing, formulation, and cell line development, enabling organizations to design advanced workflows, select high-yield cell lines, and optimize media and scale-up processes. Additionally, integration with robotics and automation supports high-throughput operations, while built-in data integrity and compliance features ensure product quality, safety, and regulatory readiness.
Genedata Bioprocess enables structured CMC data capture, efficient analysis, and seamless transfer to regulatory agencies. Supports all biotherapeutic modalities, it provides unique identifiers, genealogy tracking, and robust quality control. Applying automation to data capture, analysis, and reporting accelerates workflows, while AI/ML integration enables advanced analytics and predictive modeling. Real-world applications have demonstrated significant reductions in analysis time and improved data-driven decision-making. This unified approach empowers biopharma organizations to develop innovative biotherapeutics and novel modalities more efficiently, ensuring compliance and fostering rapid innovation.
Recommended Poster Presentation
Structured Knowledge Management Platform for Bioprocess Development
Mizue Hisano, Ph.D., Scientific Business Consultant, Genedata AG
Bioprocess development for producing biotherapeutics at quality and scale is undergoing dynamic workflow shifts. The adoption of laboratory automation, high-throughput processes, and process analytical technologies (PAT) has led to an exponential increase in the volume of data to be captured, parsed, and analyzed. To address these complexities, we introduce an end-to-end data management and workflow support platform capable of registering and interpreting a wide range of biologic modalities including proteins (e.g., IgGs, ADCs, bispecifics, enzymes), RNA and DNA therapeutics and vaccines (e.g., mRNA, DNA vaccines, ASOs), and cell and gene therapeutics (e.g., AAVs, CAR-T cells). Developed in close collaboration with leading biopharmaceutical and biotech organizations, the platform was designed to understand real-world data workflow needs. It automates cell line development from clone selection to characterization and reporting, facilitates the evaluation of numerous small-scale upstream processes (USP), manages USP and scale-up, supports downstream process (DSP) development, and facilities analytical and formulation workflows. Acting as a single source of truth, it tracks the lineage of every intermediate and batch, along with all analytical and process data, raw materials used, equipment details, and molecule and cell line information. With full, end-to-end capture and traceability of every segment of the scale up process, the platform enhances process and product understanding while strengthening quality risk management. Additionally, the structured data foundation ensures seamless integration and readiness for AI/ML tools, supporting predictive modeling, digital twins, and data-driven innovation in biotherapeutic development.
